<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765737</url>
  </required_header>
  <id_info>
    <org_study_id>EFBUR002</org_study_id>
    <nct_id>NCT02765737</nct_id>
  </id_info>
  <brief_title>Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.</brief_title>
  <official_title>Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, randomized, controlled feasibility trial to determine the safety&#xD;
      and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as&#xD;
      compared to Control alone for the treatment of second degree burns (partial thickness burns)&#xD;
      as assessed by time to healing and scarring&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, prospective, randomized, controlled feasibility trial to determine the safety&#xD;
      and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as&#xD;
      compared to Control alone for the treatment of second degree burns as assessed by time to&#xD;
      healing and scarring&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment, issues with inclusion/exclusion and choice of control&#xD;
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing Rate</measure>
    <time_frame>3 weeks</time_frame>
    <description>95% epitheliazation as assesses by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Scarring</measure>
    <time_frame>3 Months</time_frame>
    <description>Vancouver Scar Scale: consists of four variables: pliability, vascularity, height (thickness), and pigmentation. Each variable has four to six possible scores. A total score ranges from 0 to 14, whereby a score of 0 reflects normal skin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in pain</measure>
    <time_frame>3 weeks</time_frame>
    <description>Visual Analog Scale or FLACC Behavioral Pain Assessment Scale:VAS-No pain on left of line, worst pain imaginable on the right of line; FLACC- 0-2, (0 being least uncomfortable to 2 which is very uncomfortable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Treatment of Partial Thickness Burns</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dehydrated Human Amnion/Chorion Membrane</intervention_name>
    <description>Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>dHACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex Ag</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ll patients enrolled must meet all the following criteria:&#xD;
&#xD;
          1. Patient with burn injury that meets all of the following requirements:&#xD;
&#xD;
               1. Occurred within the last 48 hours&#xD;
&#xD;
               2. Wound is thermal in nature&#xD;
&#xD;
               3. Partial-thickness burn (burn extends through the epidermis and may penetrate into&#xD;
                  the dermis)&#xD;
&#xD;
               4. Total body surface area (TBSA) of burn(s) is 2-20% for all subjects&#xD;
&#xD;
               5. Burn area(s) located on smooth, flat surface&#xD;
&#xD;
               6. 2 burn areas, each with a minimum size of 16cm2 (burn areas may be two separate&#xD;
                  burns or within one large burn, see Section 9.4.2)&#xD;
&#xD;
          2. Age ≥ 12 months and ≤ 70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria will be excluded:&#xD;
&#xD;
          1. Burns meeting any of the following criteria:&#xD;
&#xD;
               1. Mechanism of injury was electrical, radiation, chemical or frostbite&#xD;
&#xD;
               2. Wound is larger than 200 cm2&#xD;
&#xD;
               3. Clinically infected burn (as judged by the investigator)&#xD;
&#xD;
               4. Previous or planned treatment of the Burn Area(s) with any of the following:&#xD;
&#xD;
                    -  Biological Skin Substitutes (including Apligraf®, Dermagraft®, etc.)&#xD;
&#xD;
          2. Patient criteria that will make patient ineligible for enrollment:&#xD;
&#xD;
               1. Ventilator dependence&#xD;
&#xD;
               2. Active malignant disease or patient is less than 1 year disease-free&#xD;
&#xD;
               3. Use of immunosuppressive agents, radiation or chemotherapy within the past 30&#xD;
                  days&#xD;
&#xD;
               4. Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia,&#xD;
                  Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
               5. Presence of any condition (including current drug or alcohol abuse, medical or&#xD;
                  psychiatric condition) that is likely to impair understanding of or compliance&#xD;
                  with the study protocol in the judgment of the Investigator&#xD;
&#xD;
               6. Presence of any condition that is likely to compromise healing in the judgment of&#xD;
                  the Investigator&#xD;
&#xD;
               7. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or&#xD;
                  women of childbearing potential who are planning to become pregnant during the&#xD;
                  time of the study OR are unwilling/unable to use acceptable methods of&#xD;
                  contraception (birth control pills, barriers, or abstinence)&#xD;
&#xD;
               8. Patient has been on any investigational drug(s) or therapeutic device(s) in the&#xD;
                  last 30 days or any previous enrollment in this study&#xD;
&#xD;
          3. Allergy or known sensitivity to any of the following:&#xD;
&#xD;
               1. Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate&#xD;
&#xD;
               2. Silver&#xD;
&#xD;
                  -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Burn Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Cairns Surgery Burn Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

